Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety

K. L. Hyrich; A. J. Silman; K. D. Watson; D. P M Symmons

doi:10.1136/ard.2004.024737

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety

K. L. Hyrich, A. J. Silman, K. D. Watson, D. P M Symmons

Research output: Contribution to journal › Article › peer-review

Abstract

Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

Original language	English
Pages (from-to)	1538-1543
Number of pages	5
Journal	Annals of the rheumatic diseases
Volume	63
Issue number	12
DOIs	https://doi.org/10.1136/ard.2004.024737
Publication status	Published - Dec 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ard.2004.024737

British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR-RA)
Hyrich, K. (PI), Watson, K. (Support team), Mowbray, K. (Support team), Kearsley-Fleet, L. (CoI), Lunt, M. (CoI) & Verstappen, S. (CoI)
Project: Research

Cite this

@article{734765dec07047a1a553dbf71debf5e8,

title = "Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety",

abstract = "Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.",

author = "Hyrich, {K. L.} and Silman, {A. J.} and Watson, {K. D.} and Symmons, {D. P M}",

year = "2004",

month = dec,

doi = "10.1136/ard.2004.024737",

language = "English",

volume = "63",

pages = "1538--1543",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "12",

}

TY - JOUR

T1 - Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety

AU - Hyrich, K. L.

AU - Silman, A. J.

AU - Watson, K. D.

AU - Symmons, D. P M

PY - 2004/12

Y1 - 2004/12

N2 - Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

AB - Anti-TNFα therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

U2 - 10.1136/ard.2004.024737

DO - 10.1136/ard.2004.024737

M3 - Article

C2 - 15242866

SN - 0003-4967

VL - 63

SP - 1538

EP - 1543

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 12

ER -

Anti-tumour necrosis factor α therapy in rheumatoid arthritis: An update on safety

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

British Society for Rheumatology Rheumatoid Arthritis Register (BSRBR-RA)

Cite this